The influence of provider characteristics and market forces on response to financial incentives.
Brock O’Neil(Vanderbilt University), Matthew J. Resnick(Vanderbilt University Medical Center), Mark D. Tyson(Vanderbilt University Medical Center), Sam S. Chang, Amy J. Graves(Vanderbilt University), Daniel A. Barocas(Vanderbilt University Medical Center), David F. Penson(Geriatric Research Education and Clinical Center)
PubMed
November 1, 2017
Cited by 5
Related Papers
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer
|New England Journal of Medicine|2013|975
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes
|European Urology|2015|688
Prostate Cancer, Version 1.2016
|Journal of the National Comprehensive Cancer Network|2016|656